PGEN Key Statistics, Chart & Performance
The current stock price of PGEN is 3.915 USD. In the past month the price decreased by -10.39%. In the past year, price increased by 329.87%.
PGEN Latest News, Press Relases and Analysis
PGEN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.92 | 415.98B | ||
| AMGN | AMGEN INC | 15.45 | 181.91B | ||
| GILD | GILEAD SCIENCES INC | 15.62 | 158.70B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.85 | 110.59B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.07 | 81.46B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 869.58 | 58.13B | ||
| INSM | INSMED INC | N/A | 43.05B | ||
| NTRA | NATERA INC | N/A | 32.02B | ||
| BIIB | BIOGEN INC | 11.01 | 27.01B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.78 | 21.23B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B |
Related stock screener links
About PGEN
Company Profile
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 143 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Company Info
PRECIGEN INC
20374 Seneca Meadows Parkway
Germantown MARYLAND 20876 US
CEO: Helen Sabzevari
Employees: 143
Phone: 13015569900
PRECIGEN INC / PGEN FAQ
What does PGEN do?
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 143 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
What is the current price of PGEN stock?
The current stock price of PGEN is 3.915 USD. The price increased by 0.9% in the last trading session.
Does PGEN stock pay dividends?
PGEN does not pay a dividend.
How is the ChartMill rating for PRECIGEN INC?
PGEN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is PGEN stock listed?
PGEN stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of PRECIGEN INC (PGEN)?
PRECIGEN INC (PGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).
What is PRECIGEN INC worth?
PRECIGEN INC (PGEN) has a market capitalization of 1.38B USD. This makes PGEN a Small Cap stock.
PGEN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to PGEN. When comparing the yearly performance of all stocks, PGEN is one of the better performing stocks in the market, outperforming 98.75% of all stocks.
PGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PGEN. PGEN has a bad profitability rating. Also its financial health evaluation is rather negative.
PGEN Financial Highlights
Over the last trailing twelve months PGEN reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS decreased by -204.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -122.18% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PGEN Forecast & Estimates
10 analysts have analysed PGEN and the average price target is 8.67 USD. This implies a price increase of 121.46% is expected in the next year compared to the current price of 3.915.
For the next year, analysts expect an EPS growth of -15.84% and a revenue growth 225% for PGEN